Test Directory
Factor VIII (8) Inhibitor Titer
Justification
Acquired factor deficiencies may occur due to the development of factor-specific inhibitory antibodies. These antibodies may also develop against factor replacement products in patients with a congenital deficiency. This test may be used to detect and quantitate inhibitory antibodies against Factor VIII.
STAT: < 24 hours (M-F)
Bethesda, Clot-based
Draw Tube: Blue Top
Sample Type: Citrated Plasma
Specimen Requirements
Sample Type | Volume Required | Minimum Volume | Stability | |
---|---|---|---|---|
PREFERRED | Citrated Plasma | Two aliquots, 1mL each | Two aliquots, 0.5mL each | Frozen (-20C): 2 weeks Frozen (-80C): 6 months |
ALTERNATIVE | - | - | - | - |
REJECTION CRITERIA | Thawed in transit, refrozen or clotted sample |
SPECIAL INSTRUCTIONS | - |
General Information
METHODOLOGY | Bethesda, Clot-based |
STAT TAT | < 24 hours (M-F) |
STAT TAT Performance | > 90% of results released in 24 hours 7 days a week |
ROUTINE TAT | < 3 days (M-F) |
ALTERNATIVE NAMES | Anti-Hemophilic Factor inhibitor, F8 inhibitor, FVIII inhibitor, clottable F8 inhibitor |
DESCRIPTION | Bethesda titer for the quantitative determination of a specific factor inhibitor against factor VIII (8). |
LIMITATIONS | - |
NORMAL RANGE | < 0.4 BU |
ASSOCIATED TESTING | - |
REFERENCES | - |
SAMPLE REPORT | Upon request |
NEW YORK STATE APPROVED | No |
Test Codes
ORDER CODE | P3071 |
CPT CODE | 85240, 85335 |
LOINC CODE | 3210-2 |